vildamet 50mg/500mg tablets coated tablet
vildagliptin 50mg metformin hydrochloride 500mg - coated tablet - vildagliptin 50mg metformin hydrochloride 500mg - metformin and vildagliptin
vildamet 50mg/850mg tablets coated tablet
vildagliptin 50mg metformin hydrochloride 850mg - coated tablet - vildagliptin 50mg metformin hydrochloride 850mg - metformin and vildagliptin
viptin plus 500mg tablet
vildagliptin inn & metformin hydrochloride bp - tablet - vildagliptin 50 mg & metformin hydrochloride 500 - metformin and vildagliptin
viptin plus 850mg tablets
vildagliptin inn & metformin hydrochloride bp - tablet - vildagliptin 50 mg & metformin hydrochloride 850 - metformin and vildagliptin
vinglyn m 50/1000 film-coated tablet
vildagliptin and metformin hydrochloride bp - film-coated tablet - vildagliptin 50 mg / tablet , metformin - metformin and vildagliptin
eucreas 501000 mg
novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - metformin hydrochloride 1000 mg; vildagliptin 50 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
eucreas 50500 mg
novartis israel ltd - metformin hydrochloride; vildagliptin - film coated tablets - metformin hydrochloride 500 mg; vildagliptin 50 mg - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:- eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.- eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.- eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
vilda 100mg od tablets
m/s. innocia lifesciences pvt. ltd. m/s. innocia lifesciences pvt. ltd. 12 balaji - vildagliptin - tablet - each tablet contains: vildagliptin100mg (as - vildagliptin
vimetso 50 mg/850 mg film-coated tablets
tad pharma gmbh heinz-lohmann-strasse 5, 27472 cuxhaven, germany - vildagliptin, metformin hydrochloride - film-coated tablet - metformin hydrochloride 850 mg vildagliptin 50 mg - drugs used in diabetes
vigliptin 50mg tablet
dawa limited plot no.7879/8,baba dogo road - ruaraka,p.o box - vildagliptin - tablet - each tablet contain :vildagliptin 50mg - vildagliptin